1800 244 735

Helpline (02) 9874 9777

Huntington's Disease Therapeutics Conference 2014: day 2

HDBuzz reports from the second day of science at the Huntington’s disease therapeutics conference in Palm Springs.

Morning session: Cells, Circuits and Systems

09:06 – The second day of the annual HD therapeutics conference starts with a series of talks on “Cells, circuits and systems”

But first… watch Olympian & world champion rower Sarah Winckless address the Huntington’s Disease Therapeutics Conference

09:09 – The scientists speaking this morning are interested in communication breakdown in the HD brain and how to fix it

09:14 – Mike Levine, ULCA, explains how the “striatum” is wired together. This is the most vulnerable part of the brain in HD patients

09:18 – The brain is complicated! In HD, degenerating tissues are composed of a wide range of cell types, wired together in complex circuits

09:21 – Bal Khakh, UCLA, studies a star-shaped type of cell called an “astrocyte”. The brain is stuffed with these non-neuronal cells

09:22 – In mice, if we put the mutant HD gene in only astrocytes, the brain gets sick. This got Bal interested in astrocytes in HD patients

09:26 – Though astrocytes don’t fire electrical signals like brain cells called neurons, they have really important functions

09:40 – Could changes in astrocytes in the HD brain contribute to dysfunction in other brain cells? Bal is using HD mice to try to find out

09:43 – In HD mice, fixing astrocyte problems leads to improvement in symptoms

09:51 – Lynn Raymond, UBC, studies changes in a specific “synapse” in the HD brain. Synapses are connections between “neurons” in the brain

09:55 – Raymond measures electrical and chemical activity in these synapses in healthy mice and those with the HD mutation

10:00 – Raymond grows neurons from the cortex (surface of the brain) and striatum (deeper part) together to study how they interact

10:08 – Lynne Raymond addressing the conference on the function of synapses http://t.co/RTyfwMzjZk

10:09 – Raymond has found that there are electrical differences in the behavior of the striatal neurons but it’s not clear why

10:10 – Raymond’s aim is to use the cortex-striatum neuron mixture, called co-culture, to test drugs for HD

10:28 – Next up, Mark Bevan of Northwestern University. Bevan studies the electrical activity in ‘brain slices’ from HD mice.

10:33 – Bevan has found abnormally low activity in a part of the striatum called the subthalamic nucleus in HD mice

10:33 – An electrical switch called the NMDA receptor seems to be responsible for this abnormality.

10:40 – Bevan is trying to figure out why this abnormal activity occurs. Work like this is essential to understanding how to fix human brains

11:17 – Anton Reiner, UT, has a long standing interest in mapping patterns of cell loss in HD patient brains. Which cells are first to go?

11:22 – Understanding which brain cell type is most vulnerable in HD might help us understand why some cells die and others don’t

11:24 – While Reiner has studied human brain tissues, his lab also works with HD mice to look at very early changes in the HD brain

11:29 – Reiner is working now to try to correlate patterns of change that he sees in HD mouse brains with their behavioral symptoms

11:34 – Reiner is interested in undersanding the origin of a movement symptom called “dystonia” in HD

11:37 – Dystonia, twisted and abnormal movements or postures, can be a debilitating symptom of HD, partricularly in later stages

11:37 – Reiner is studying the connection between patterns of cell loss in the HD brain and the presence of dystonia as a symptom

11:47 – George Rebec, Indiana University, measures the activity of brain cells in HD mice that are awake and behaving

11:49 – His mice wear “headsets” that record brain cell activity while the mice actively move around their cages

11:52 – Like Raymond, and others, Rebec is interested in communication between the “cortex” and “striatum”, and how this goes wrong in HD

11:58 – While observing HD mice, Rebec notices that they don’t like to sit still as much as normal mice, they seem restless

11:59 – Rebec can detect brain activity patterns that correlate with this restlessness, maybe explaining it’s cause

12:01 – He’s using a genetic trick in mice to get rid of the mutant HD gene in the cortex, but not the striatum, to figure out who’s in charge

12:07 – These mice seem a bit less restless, and a bit less “stubborn” in their behavior patterns

12:10 – Rebec’s take home message is “improper communication can be dangerous”, so fixing cortical problems might help other brain areas in HD

Sunset conclusions

This afternoon we took time to view and digest the 100 posters presented by the 300 scientists attending the meeting. These posters represent a huge amount of work from dozens of laboratories around the world. Most is unpublished, much is incredibly innovative and all is shared freely to foster collaboration and accelerate the development of treatments.

After that we heard from James Bradner of the Dana-Farber Cancer Institute. Bradner developed a drug molecule for a rare type of cancer then made the drug freely available to any researcher worldwide, leading to an explosion of therapeutic progress in many other diseases. We recalled Jonas Salk’s response to an interviewer asking whether he’d patent his life-saving polio vaccine: “Could you patent the sun?”

At HDBuzz, we are unashamed fans of sharing and the free flow of information. A spirit of openness runs through the HD scientific and patient community, fertilizing progress towards treatments.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 8 January, 2021

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more

Uncovering the dark side of DNA repair to design HD treatments

Published date: 22 December, 2020

A gene known as ‘MSH3’, which encodes a protein involved in fixing and maintaining our DNA, has become a hot topic in Huntington’s research since being implicated as a key driver of the disease by multiple genetic studies. In a recent publication, a team of scientists from the National University of Ireland, Galway, have provided ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 2

Published date: 1 November, 2020

The second day of the HSG conference was another busy day of presentations from HD researchers and clinicians. The day kicked off with a talk from Vaccinex who gave us an overview of their work on the SIGNAL clinical trial. Unfortunately, pepinemab, the medicine tested in this trial, did not influence HD symptoms and the ... Read more

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus – Day 1

Published date: 30 October, 2020

The Huntington Study Group (HSG) is a clinical research network focused exclusively on HD. Yesterday the HSG annual conference began with a schedule jam-packed with virtual talks from researchers, clinicians and different companies who are all working towards finding new medicines for HD. The day encompassed many interesting presentations which covered a lot of the ... Read more

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Published date: 22 October, 2020

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation to branaplam. An existing drug…for huntingtin lowering? The pharmaceutical company Novartis has announced that the U.S. Food and Drug Administration ... Read more

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more